Human Reproduction Update, Vol.2, No.6 pp.519-529, 1996
© European Society of Human Reproduction and Embryology 1996; all rights reserved
Chlamydial pelvic inflammatory disease
0 Department of Infectious Disease Epidemiology, National Public Health Institute, Helsinki, Finland z Corresponding author at: Department of Obstetrics and Gynecology, University of Helsinki, Haartmaninkatu 2, 00290 Helsinki, Finland. Email: jpaavone@c.Helsinki.Fi
Abstract
Pelvic inflammatory disease (PID) is the most important complication present in the female lower genital tract, causing major medical, social and economic problems. Although PID can be caused by multiple micro-organisms, it results most frequently from the ascent of sexually transmitted Chlamydia.trachomatis or Neisseria gonorrhoeae infections from the cervix to the upper genital tract. The importance of cervical chlamydial infection in the pathogenesis of PID is well recognized. Recent data from many developed countries have shown a striking decrease in the incidence of gonococcal infections, while the rates of chlamydial infections remain high in most countries. Complications of PID are common and usually irreversible. Emerging evidence suggests that universal or selected screening of defined populations for cervical chlamydial infection leads to a dramatic reduction in the incidence of PID. Recent technological advances should further enhance efforts to prevent chlamydial infection and PID. Gene amplification-based diagnostic tests, screening by testing first-void urine, and single dose antimicrobial therapy greatly facilitate chlamydia control programmes. Thus, screening for chlamydia is the key approach in the secondary prevention of PID. The obvious challenge is to make screening for chlamydia the standard for health care for young, sexually active individuals. Since PID is the most important consequence of sexually transmitted bacterial infections, it is also imperative to develop better treatments to prevent the long-term sequelae of this disease. The development and implementation of new and effective intervention programmes for prevention and control of PID is one of the major challenges for the year 2000 and beyond.
Keywords: C.trachomatis/Neisseria gonorrhoeae/pelvic inflammatory disease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Petrovay, E. Balla, I. Nemeth, and E. Gonczol Genotyping of Chlamydia trachomatis from the endocervical specimens of high-risk women in Hungary J. Med. Microbiol., June 1, 2009; 58(6): 760 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mahilum-Tapay, V. Laitila, J. J Wawrzyniak, H. H Lee, S. Alexander, C. Ison, A. Swain, P. Barber, I. Ushiro-Lumb, and B. T Goh New point of care Chlamydia Rapid Test bridging the gap between diagnosis and treatment: performance evaluation study BMJ, December 8, 2007; 335(7631): 1190 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Saison, L. Mahilum-Tapay, C.-E. E. Michel, N. D. Buttress, E. C. B. Nadala Jr., J. P. V. Magbanua, E. M. Harding-Esch, M. O. Villaruel, L. Canong, R. L. Celis, et al. Prevalence of Chlamydia trachomatis Infection among Low- and High-Risk Filipino Women and Performance of Chlamydia Rapid Tests in Resource-Limited Settings J. Clin. Microbiol., December 1, 2007; 45(12): 4011 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sziller, O. Babula, A. Ujhazy, B. Nagy, P. Hupuczi, Z. Papp, I.M. Linhares, W.J. Ledger, and S.S. Witkin Chlamydia trachomatis infection, Fallopian tube damage and a mannose-binding lectin codon 54 gene polymorphism Hum. Reprod., July 1, 2007; 22(7): 1861 - 1865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Anttila, L. Tenkanen, S. Lumme, M. Leinonen, R. E. Gislefoss, G. Hallmans, S. Thoresen, T. Hakulinen, T. Luostarinen, P. Stattin, et al. Chlamydial Antibodies and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 385 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Novak, L. Lindholm, M. Jonsson, and R. B. Karlsson A Swedish cost-effectiveness analysis of community-based Chlamydia trachomatis PCR testing of postal urine specimens obtained at home Scand J Public Health, October 1, 2004; 32(5): 324 - 332. [Abstract] [PDF]
|
|
|
|
 |
|
 E Honey, C Augood, A Templeton, I Russell, J Paavonen, P-A Mardh, A Stary, and B Stray-Pedersen Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies Sex Transm Inf, December 1, 2002; 78(6): 406 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.H. Kinnunen, H-M. Surcel, M. Lehtinen, J. Karhukorpi, A. Tiitinen, M. Halttunen, A. Bloigu, R.P. Morrison, R. Karttunen, and J. Paavonen HLA DQ alleles and interleukin-10 polymorphism associated with Chlamydia trachomatis-related tubal factor infertility: a case-control study Hum. Reprod., August 1, 2002; 17(8): 2073 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Maxion and K. A. Kelly Chemokine Expression Patterns Differ within Anatomically Distinct Regions of the Genital Tract during Chlamydia trachomatis Infection Infect. Immun., March 1, 2002; 70(3): 1538 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pimenta, M. Catchpole, M. Gray, J. Hopwood, and S. Randall Evidence based health policy report: Screening for genital chlamydial infection BMJ, September 9, 2000; 321(7261): 629 - 631. [Full Text]
|
|
|
|
|
|
A. Kinnunen, P. Molander, A. Laurila, I. Rantala, R. Morrison, M. Lehtinen, R. Karttunen, A. Tiitinen, J. Paavonen, and H.-M. Surcel Chlamydia trachomatis reactive T lymphocytes from upper genital tract tissue specimens Hum. Reprod., July 1, 2000; 15(7): 1484 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. LaVerda, L. N. Albanese, P. E. Ruther, S. G. Morrison, R. P. Morrison, K. A. Ault, and G. I. Byrne Seroreactivity to Chlamydia trachomatis Hsp10 Correlates with Severity of Human Genital Tract Disease Infect. Immun., January 1, 2000; 68(1): 303 - 309. [Abstract] [Full Text] [PDF]
|
|